SAFETY AND EFFICACY OF THE FITUSIRAN REVISED ANTITHROMBIN-BASED DOSE REGIMEN IN PEOPLE WITH HAEMOPHILIA A OR B, WITH OR WITHOUT INHIBITORS (ATLAS-OLE)

Background: Fitusiran, a Subcutaneous (SC) investigational siRNA therapeutic, lowers Antithrombin (AT) to increase thrombin generation and rebalance haemostasis in people with Haemophilia (PwH) A or B, regardless of inhibitor status. We report interim safety and efficacy of the fitusiran Antithrombi...

Full description

Bibliographic Details

Published in:	Hematology, Transfusion and Cell Therapy
Main Authors:	Guy-Young, Kaan-Kavakli, S W-Pipe, Alok-Srivastava, Juliana-Aragao, L A-Menapace, Chuanwu-Zhang, Marja-Puurunen, Marek-Demissie, Gili-Kenet
Format:	Article
Language:	English
Published:	Elsevier 2024-10-01
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137924012811